chloroquine + paclitaxel

Chloroquine + paclitaxel is a combination therapy, most notably investigated in a novel composite liposomal system that co-encapsulates both drugs for the treatment of paclitaxel-resistant carcinoma. The combination leverages the ability of chloroquine to inhibit autophagy and competitively bind with multidrug-resistance transporters, thereby sensitizing cancer cells to paclitaxel. This approach has demonstrated superior anticancer efficacy compared to administering each drug separately or as a mixture of individual liposomes[1][3]. The co-encapsulation allows for simultaneous delivery and synergistic effects, reducing toxicity associated with free forms of both drugs[1][3].

Other names

chloroquine and paclitaxelchloroquine/paclitaxel combinationPTX+CQ liposome